
FY21 Strong financial performance, strategic transformation
26/04/2022 Instem plc
Instem has reported FY21 results consistent with the January trading statement and in line with our forecasts. Despite […]

Bringing drugs to market faster
25/02/2022 Instem plc
Instem offers an opportunity to invest in a business with two specific attractions – (1) The group is […]

Trading in-line, all key metrics improving
26/01/2022 Instem plc
Instem has delivered a positive trading update for the year to 31 December 2021, reporting like-for-like (LFL) revenue […]

Strong organic and acquisitive growth
29/09/2021 Instem plc
Instem has once again delivered a strong set of interim results in our view, with the growth story […]

A strategic move in Switzerland
01/09/2021 Instem plc
Instem has announced the (earnings enhancing) acquisition of PDS Pathology Data Systems Ltd (“PDS”) a Swiss-based life sciences […]

H1 21 trading: strength across the board
19/07/2021 Instem plc
Instem’s update for the six months to 30 June 2021 (H1 21E) confirms that trading was in line […]

FY 20A: Solid growth, despite COVID-19
12/04/2021 Instem plc
Instem has reported FY 20A results consistent with its Jan-21 trading statement and in line with our forecasts. […]

Transformational deal in clinical trial analysis
22/03/2021 Instem plc
Instem has announced that it has exchanged contracts to acquire d-Wise Technologies Inc (“d-wise”) a US-based clinical trial […]

Strengthening the position in Discovery
01/03/2021 Instem plc
Instem has announced the (earnings enhancing) acquisition of UK-based Discovery software solutions provider The Edge Software Consultancy Ltd […]

Strong end to 2020 – positioned for growth
14/01/2021 Instem plc
Instem has delivered a positive trading update for the year to 31 December 2020 – revenue growth was […]

Momentum remains strong
28/09/2020 Instem plc
Instem has delivered strong H1 20A results in our view. Despite the backdrop of COVID-19, all three business […]

Strong trading, successful fundraise
20/07/2020 Instem plc
Instem’s H1 20E trading update confirms that trading was in line with the Board’s expectations during the period. […]